Overview of Skin Cancers for General Practitioners

Tarek Haykal

Dysplastic Nevi: Navigating the Risk Landscape

Scripps Health

B. Kelley

Advances in the Treatment of Melanoma

Masterclasses in Dermatology

D. Fisher

ASCO® 2024 Summary: "My Personal Highlights in Melanoma"

2024 ASCO® Annual Meeting Insights Hub

S. Patel

FDA Approval of Lifileucel for Unresectable or Metastatic Melanoma: …

Stanford Medicine

A. Betof Warner

The NADINA Trial - A Paradigm Shift in Melanoma Treatment

Oncology Data Advisor

M. Hadfield

AAD 2024 Insights: What's New In Nail Tumors

AAD 2024

J. Dominguez-Cherit

AAD 2024 Insights: The Latest Advances in the Treatment of Melanoma

AAD 2024

V. Sondak

The Role of Adjuvant IO vs. Targeted Therapy for BRAF V600-Mutant St…

Tarek Haykal

Sun Safety and Melanoma Awareness: Expert Tips on Preventing Sun Dam…

Oncology Data Advisor

T. Knight, M. Hadfield

ASCO® 2024 Summary: "Highlights in Early Stage, 1L Metastatic, and R…

2024 ASCO® Annual Meeting Insights Hub

D. Johnson

ASCO® 2024 Summary: "Insights in Melanoma"

2024 ASCO® Annual Meeting Insights Hub

O. Hamid

ASCO® 2024 Insights: "COMBI-AD Study - Dabrafenib + Trametinib in St…

2024 ASCO® Annual Meeting Insights Hub

A. Hauschild

NCCN Guidelines Updates for the Management of Cutaneous Melanoma: Ne…

Vanderbilt University Medical Center (VUMC)

D. Johnson

ASCO® 2024 Summary: "Highlights in Melanoma - Neoadjuvant and Adjuva…

2024 ASCO® Annual Meeting Insights Hub

Z. Eroglu

Imaging Considerations for the Dermatologist

Masterclasses in Dermatology

C. Bakewell

ASCO® 2024 Insights: "NADINA Trial - Neoadjuvant Nivo + Ipi in Macro…

2024 ASCO® Annual Meeting Insights Hub

C. Blank

Long-Term Side Effects Associated With IO Treatment vs. TT in Adjuva…

Mees Egeler

Advantages & Disadvantages of Adjuvant IO vs. Targeted Treatment for…

Alexander van Akkooi

ESMO 2024 Summary: Key Metastatic and Neoadjuvant Melanoma Trials

2024 ESMO Annual Meeting Insights Hub

D. Johnson